AlphaCrest Capital Management’s Cardinal Health CAH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-49,614
Closed -$3.31M 181
2022
Q3
$3.31M Sell
49,614
-3,007
-6% -$191K 0.2% 74
2022
Q2
$2.75M Buy
52,621
+21,303
+68% +$1.21M 0.13% 190
2022
Q1
$1.78M Sell
31,318
-17,865
-36% -$957K 0.1% 280
2021
Q4
$2.53M Sell
49,183
-257
-0.5% -$12.6K 0.09% 312
2021
Q3
$2.44M Sell
49,440
-2,645
-5% -$143K 0.13% 211
2021
Q2
$2.97M Buy
52,085
+39,573
+316% +$2.31M 0.13% 215
2021
Q1
$760K Buy
12,512
+1,361
+12% +$75.1K 0.04% 617
2020
Q4
$597K Sell
11,151
-33,885
-75% -$1.76M 0.05% 553
2020
Q3
$2.11M Buy
45,036
+11,199
+33% +$575K 0.23% 82
2020
Q2
$1.77M Sell
33,837
-21,160
-38% -$1.09M 0.29% 55
2020
Q1
$2.64M Sell
54,997
-31,970
-37% -$1.66M 0.32% 32
2019
Q4
$4.4M Buy
86,967
+79,367
+1,044% +$4.1M 0.36% 27
2019
Q3
$359K Buy
+7,600
New +$347K 0.02% 1051
2019
Q2
Sell
-4,527
Closed -$218K 1027
2019
Q1
$218K Sell
4,527
-16,170
-78% -$810K 0.03% 758
2018
Q4
$923K Buy
+20,697
New +$1.08M 0.27% 82

Other funds holding CAH

AlphaCrest Capital Management's CAH Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Cardinal Health (CAH) in Q4 2022, closing a stake of 49,614 shares — an estimated $3.31M sold.

AlphaCrest Capital Management first reported a position in CAH in Q4 2018 and held it in 15 quarters. The position peaked at $4.4M in Q4 2019. 930 funds tracked by Wall St. Rank hold CAH as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Cardinal Health position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 49,614 Cardinal Health shares in Q4 2022, an estimated $3.31M.
  • AlphaCrest Capital Management first reported a position in Cardinal Health in Q4 2018 and held it in 15 quarters.
  • AlphaCrest Capital Management's Cardinal Health position peaked at $4.4M in Q4 2019.
  • 930 funds tracked by Wall St. Rank held Cardinal Health as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.